Intra-Cellular Therapies, Inc.
ITCI
주식 순위
#1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
주가
$131.87
마지막 동기화: 2025-04-02
시가총액
$12.68B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Intra-Cellular Therapies, Inc. (ITCI)
카테고리
Healthcare
Intra-Cellular Therapies, Inc. (ITCI)의 매출
Dec 2024 기준 매출 TTM: $680.64M
Intra-Cellular Therapies, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $680.64M입니다. 2023년에 회사는 $464.37M의 수익을 올렸으며 이는 2022년의 $249.13M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Intra-Cellular Therapies, Inc.의 수익 기록 (2013 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $680.64M | -0.03% |
| 2024 | $680.85M | 46.62% |
| 2023 | $464.37M | 86.40% |
| 2022 | $249.13M | 204.91% |
| 2021 | $81.71M | 262.65% |
| 2020 | $22.53M | 37,071.49% |
| 2019 | $60.61K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $245.84K | -25.66% |
| 2016 | $330.70K | 261.96% |
| 2015 | $91.36K | -84.17% |
| 2014 | $577.30K | -78.91% |
| 2013 | $2.74M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 871.39% |
IN
|
